Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6130089 | 0.94 | LMNA (0.45) | LMNACTSLCTSBFOLH1BLM | |
| SCHEMBL2124275 | 0.87 | CTSL (0.42) | LMNACTSLCTSB | |
| SCHEMBL16899661 | 0.83 | LMNA (0.38) | LMNAFOLH1 | |
| SCHEMBL6130047 | 0.82 | LMNA (0.48) | LMNACTSLCTSBBLM | |
| SCHEMBL18226959 | 0.80 | — | — | |
| SCHEMBL17426963 | 0.79 | EPHX1 (0.39) | LMNACTSLCTSBBLM | |
| SCHEMBL17426957 | 0.79 | EPHX1 (0.39) | LMNACTSLCTSBBLM | |
| SCHEMBL17426962 | 0.79 | EPHX1 (0.39) | LMNACTSLCTSBBLM | |
| SCHEMBL17426961 | 0.79 | EPHX1 (0.39) | LMNACTSLCTSBBLM | |
| SCHEMBL17426946 | 0.79 | EPHX1 (0.39) | LMNACTSLCTSBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | CD2BP2, CD2, CD47 | LMNA 4459/4885CTSL 2926/4885CTSB 2885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.